Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATP-TCA-guided chemotherapy versus standard carboplatin + docetaxel for advanced non-small cell lung cancer or mesothelioma
ACTRN12611000728932Phase 2Recruiting
- Sponsor
- Ballarat Cancer Research Centre
- Start
- Jun 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of carboplatin, docetaxel, pemetrexed, vinorelbine, gemcitabine and 2 more in non-small cell lung cancer (NSCLC) and mesothelioma (2 arms), sponsored by Ballarat Cancer Research Centre. Primary endpoint: Partial response rate. Started Jun 2010; status: recruiting.
02
Drugs
carboplatindocetaxelpemetrexedvinorelbinegemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)mesothelioma
Beyond the preview
Go deeper on ACTRN12611000728932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000728932.